Auro Laboratories
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
May 29 (Reuters) - Auro Laboratories Ltd AURL.BO:
APPOINTS NITESH BOHRA AS CFO
Source text: ID:nBSE4dHSX5
Further company coverage: AURL.BO
(([email protected];))
May 29 (Reuters) - Auro Laboratories Ltd AURL.BO:
APPOINTS NITESH BOHRA AS CFO
Source text: ID:nBSE4dHSX5
Further company coverage: AURL.BO
(([email protected];))
Dec 22 (Reuters) - Auro Laboratories Ltd AURL.BO:
NAMES SHAAN JAIN AS CFO
Source text for Eikon: ID:nBSE2bKb8v
Further company coverage: AURL.BO
(([email protected];;))
Dec 22 (Reuters) - Auro Laboratories Ltd AURL.BO:
NAMES SHAAN JAIN AS CFO
Source text for Eikon: ID:nBSE2bKb8v
Further company coverage: AURL.BO
(([email protected];;))
Sept 25 (Reuters) - Auro Laboratories Ltd AURL.BO:
AMIT MAHIPAT SHAH RESIGNED AS CHIEF FINANCIAL OFFICER OF CO WEF OCTOBER 1, 2023
Source text for Eikon: ID:nBSE4qKbv3
Further company coverage: AURL.BO
(([email protected];))
Sept 25 (Reuters) - Auro Laboratories Ltd AURL.BO:
AMIT MAHIPAT SHAH RESIGNED AS CHIEF FINANCIAL OFFICER OF CO WEF OCTOBER 1, 2023
Source text for Eikon: ID:nBSE4qKbv3
Further company coverage: AURL.BO
(([email protected];))
Aug 23 (Reuters) - Auro Laboratories Ltd AURL.BO:
APPROVED CAPACITY EXPANSION IN EXISTING UNIT OF CO
INVESTMENT REQUIRED AT 400 MILLION RUPEES
Source text for Eikon: ID:nBSE7vXptn
Further company coverage: AURL.BO
(([email protected];;))
Aug 23 (Reuters) - Auro Laboratories Ltd AURL.BO:
APPROVED CAPACITY EXPANSION IN EXISTING UNIT OF CO
INVESTMENT REQUIRED AT 400 MILLION RUPEES
Source text for Eikon: ID:nBSE7vXptn
Further company coverage: AURL.BO
(([email protected];;))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Auro Laboratories do?
Auro Laboratories Limited is a pharmaceutical company specializing in manufacturing Active Pharmaceutical Ingredients, Intermediates, and Generic Formulations, with a primary focus on Anti-Diabetic Drugs.
Who are the competitors of Auro Laboratories?
Auro Laboratories major competitors are Parnax Lab, Accretion Pharma., Panchsheel Organics, Kimia Biosciences, Chemkart India, Natural Capsules, Quest Laboratories. Market Cap of Auro Laboratories is ₹157 Crs. While the median market cap of its peers are ₹158 Crs.
Is Auro Laboratories financially stable compared to its competitors?
Auro Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Auro Laboratories is 2.14 and is ranked 7 out of its 8 competitors.
Does Auro Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Auro Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Auro Laboratories allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress
How strong is Auro Laboratories balance sheet?
Balance sheet of Auro Laboratories is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Auro Laboratories improving?
The profit is oscillating. The profit of Auro Laboratories is ₹3.53 Crs for TTM, ₹1.84 Crs for Mar 2025 and ₹7.79 Crs for Mar 2024.
Is the debt of Auro Laboratories increasing or decreasing?
The net debt of Auro Laboratories is decreasing. Latest net debt of Auro Laboratories is ₹18.32 Crs as of Mar-26. This is less than Mar-25 when it was ₹43.76 Crs.
Is Auro Laboratories stock expensive?
Auro Laboratories is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Auro Laboratories is 44.9, while 3 year average PE is 43.89. Also latest EV/EBITDA of Auro Laboratories is 18.13 while 3yr average is 24.91.
Has the share price of Auro Laboratories grown faster than its competition?
Auro Laboratories has given better returns compared to its competitors. Auro Laboratories has grown at ~14.55% over the last 2yrs while peers have grown at a median rate of -20.68%
Is the promoter bullish about Auro Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Auro Laboratories is 52.18% and last quarter promoter holding is 52.18%.
Are mutual funds buying/selling Auro Laboratories?
The mutual fund holding of Auro Laboratories is stable. The current mutual fund holding in Auro Laboratories is 0.01% while previous quarter holding is 0.01%.